Fintel on MSN14h
Citigroup Initiates Coverage of BioNTech SE - Depositary Receipt () (BNTX) with Buy Recommendation
Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...
BioNTech (NASDAQ:BNTX) Now Covered by Analysts at Citigroup
Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...
BioNTech initiated with a Buy at Citi
Citi analyst Geoff Meacham initiated coverage of BioNTech (BNTX) with a Buy rating and $145 price target Healthcare policy remains a key ...
BioNTech SE (NASDAQ:BNTX) Analysts Are Cutting Their Estimates: Here's What You Need To Know
BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
Analysts Set Expectations for BioNTech FY2024 Earnings
Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...
BioNTech Stock Drops as Sales Outlook Disappoints
BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.
BioNTech (NasdaqGS:BNTX) Faces Sales Decline To €2,751 Million In 2024 And Projects Lower 2025 Revenue
BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...
Is BioNTech SE (BNTX) The Best Immunology Stock To Buy Now?
We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...
BioNTech price target lowered to $151 from $172 at Truist
Truist analyst Asthika Goonewardene lowered the firm’s price target on BioNTech (BNTX) to $151 from $172 and keeps a Buy rating on the shares.